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Background: Serratiopeptidase is a proteolytic enzyme prescribed in various specialities like surgery,
orthopaedics, otorhinolaryngology, gynaecology and dentistry for its anti-inﬂammatory, anti-edemic and
analgesic effects. Some anecdotal reports suggest it to possess anti-atherosclerotic effects also, due to its
ﬁbrinolytic and caseinolytic properties. Despite being widely used there are few published studies
regarding its efﬁcacy. Thus, evidence regarding its clinical utility is needed.
Objective: To evaluate the existing evidence regarding efﬁcacy and safety of Serratiopeptidase in clinical
practice.
Evidence acquisition: A systematic review of all the published articles of Serratiopeptidase using Cochrane
Library, PubMed, MEDLINE, Clinical Trials.gov, Google, Dogpile and a manual search of bibliographies was
conducted from 1st May 2011 till 15th July 2012. Further emails were sent to all the leading pharma-
ceuticals who are manufacturing this enzyme preparation for any additional information. All studies
related to Serratiopeptidase which included Randomised controlled trials (RCTs), meta-analysis of RCTs,
placebo-controlled, single-blind, double-blind, open label, prospective trials as well as preclinical studies
were screened and analysed. The scientiﬁc credibility of the studies was graded according to the Scottish
Intercollegiate Guidelines Network (SIGN) grading checklist. A total of 24 studies on clinical efﬁcacy of
Serratiopeptidase met the inclusion criteria.
Evidence synthesis: Serratiopeptidase search on Cochrane library revealed 16 results among which 9 were
Cochrane Central Register of Controlled Trials 2011, issue 4 studies and 7 were Cochrane Central Register
of Controlled trials 2012, issue 3 studies. Of these 16 results, 11 were RCTs on efﬁcacy of Serratiopepti-
dase. PubMed search also revealed 74 results which showed 16 Clinical trials, out of which 9 were RCTs
related to Serratiopeptidase. Bandolier online edition (retrieved on 1/5/2011) showed a review ’Serra-
tiopeptidase-ﬁnding the evidence’ which included 9 RCTs. The evidence supporting the use of Serra-
tiopeptidase as anti-inﬂammatory and analgesic agent is based on clinical studies which are of poor
methodology. Only few RCTs, which are usually placebo control, with a small sample size are there. The
dose and duration of treatment was not speciﬁed in some studies, and the outcome of the study was not
clearly deﬁned in a few. Data on the safety and tolerability of Serratiopeptidase is lacking in these studies.
Limitations: A thorough search of literature was done to include all the relevant studies but we may have
unknowingly missed a few of those studies which have not been published or registered with any of
these search engines. The clinical evidence obtained have been graded according to the "Scottish
Intercollegiate Grading Network" checklist by two separate reviewers and then coordinated together to
give the ﬁnal grading. Any disagreement between the two reviewers was resolved by discussion with the
third reviewer. This was done to minimise bias but still the risk of bias cannot be completely ruled out.
Conclusion: Serratiopeptidase is being used in many clinical specialities for its anti-inﬂammatory, anti-
edemic and analgesic effects. It is even being promoted as a health supplement to prevent cardiovascular
morbidity. The existing scientiﬁc evidence for Serratiopeptidase is insufﬁcient to support its use as an
analgesic and health supplement. The data on long-term safety of this enzyme is lacking. Evidence based
recommendations on the analgesic, anti-atherosclerotic efﬁcacy, safety and tolerability of Serratio-
peptidase are needed.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.bile).
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Serratiopeptidase (Serratia E-15 protease also known as serral-
ysin/serratia-protease/serrapeptase) is a proteolytic enzyme thatd. All rights reserved.
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formulation of this enzyme is being used commonly in various
specialities like surgery, orthopaedics, otolaryngology, gynaecology
and dentistry for its anti-inﬂammatory and anti-edemic properties.
The use of enzymes like trypsin,8 chymotrypsin,9 bromelain10 as
anti-inﬂammatory agents came into practice after it was observed
during 1950s in USA that parenteral trypsin could be used to relieve
post-surgical inﬂammation and that due to traumatic injury caused
by sports8 as well as inﬂammation due to conditions like rheu-
matoid arthritis, ulcerative colitis, and atypical viral pneumonia.
This observation was soon followed by the use of Serratio-
peptidase2 for its anti-inﬂammatory effects in Japan for the ﬁrst
time. Later during 1960s these parenteral enzyme formulations
were replaced by their enteric coated successors to be used orally.
During 1980s and 1990s it was proposed by separate research
conducted in Europe and Japan that Serratiopeptidasewas themost
effective agent in reducing inﬂammation among all other enzyme
preparations.1,3 Serratiopeptidase hence, has been used for almost
40 years in Japan and Europe for pain and inﬂammation due to
arthritis, trauma, surgery, sinusitis, bronchitis, carpal tunnel syn-
drome and painful swelling of breasts. Apart from its anti-
inﬂammatory activity, Serratiopeptidase is also said to possess
analgesic and anti-atherosclerotic effects. This systematic review is
an attempt to critically examine the available evidencewhich exists
as regards the efﬁcacy and safety of Serratiopeptidase.
2. Evidence acquisition
2.1. Search criteria
To identify articles, we systematically searched electronic da-
tabases and commercial websites for published and unpublished
studies, applied inclusion criteria and performed quality appraisals.
The databases searched include the Cochrane Library, PubMed,
MEDLINE, the Controlled trials registry Clinical Trials.gov, Google,
Dogpile. A manual search from reference lists of relevant articles
was conducted and Pharmaceutical companies were contacted
through emails for additional information on pharmacokinetics,
pharmacodynamics, efﬁcacy and safety of Serratiopeptidase. TheFig. 1. Preferred reporting items for systematic reviews and meta-analysis (PRISMA)1following search terms were used either independently of each
other or in combinations: Serratiopeptidase, serrapeptase, serra-
tiopeptidase, proteolytic enzymes, pharmacokinetics, pharmaco-
dynamics, anti-inﬂammatory agents, danzen, serratiapeptase,
serralysin, adverse drug reactions.
2.2. Inclusion criteria
Eligible studies were required to report results on Serratio-
peptidase efﬁcacy and safety. All articles available on efﬁcacy were
included. All articles were required to be complete and available in
english. Studies were selected for inclusion in our systematic re-
view if they met the inclusion criteria: double-blind, single-blind,
open label, placebo-controlled, randomised controlled trials, meta-
analysis of RCTs, prospective trials or preclinical studies.
A total of 24 studies on clinical efﬁcacy of Serratiopeptidase met
the inclusion criteria. Among which 18 were clinical trials
(including 14 RCTs, 3 prospective trials and in 1 trial study design
not stated) and 6 were preclinical animal studies. As Serratio-
peptidase has been in clinical use for inﬂammation and pain for
a number of years and is being promoted these days for its anti-
atherosclerotic effects also. But data on its analgesic and anti-
atherosclerotic efﬁcacy was found to be lacking. The RCTs were
only a few in numbers (14 RCTs in total excluding the duplicated
studies, 11 RCTs found on Cochrane Library and 9 on PubMed
search). They had a limited population, not more than 150 patients
per group in any of the studies and were of short duration.
Therefore prospective studies as well as preclinical studies were
also included to appraise evidence on efﬁcacy of Serratiopeptidase.
2.3. Quality appraisal
Critical appraisal of studies was conducted using PRISMA11
statement (Fig. 1) while the Scottish Intercollegiate Guidelines
Network (SIGN)12 grading for RCTs was used for original studies by
two separate reviewers and then coordinated together to validate
the ﬁnal grading. This was done to facilitate transparent and
comprehensive reporting of results. Any disagreement between the
two reviewers was resolved by discussion with the third reviewer.1
ﬂow diagram of studies included in the review of efﬁcacy of serratiopeptidase.
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Search on Cochrane Library database using keyword ‘Serratio-
peptidase’ revealed 16 results among which 8 were RCTs related to
efﬁcacy of Serratiopeptidase. A repeated search on the same data-
base using keyword ‘Serrapeptase’ revealed 9 results among which
6 were RCTs. Therefore, a total of 11 RCTs were included in our
review excluding those which were duplicated and where full text
was not available.
PubMed search using keywords ‘Serratiopeptidase’ or ‘Serra-
peptase’ revealed 74 results which showed 16 clinical trials out of
which 9 were RCTs related to efﬁcacy of Serratiopeptidase. Thus,
a total of 14 RCTs were included in our review. Only those studies
were included which were published and where full text was
available excluding those with duplicate results. Various published
studies have reﬂected the use of Serratiopeptidase for its anti-
inﬂammatory, anti-edemic and analgesic effects. Some anecdotal
studies suggest it to possess anti-atherosclerotic effects also.
There were 6 clinical studies (Table 1) supporting the anti-
inﬂammatory effects of Serratiopeptidase. But among these clini-
cal trials the dose and duration of therapy was not speciﬁed in 2 of
these studies and were having small sample size, 3 were placebo-
controlled trials, while 1 study with active comparator Seaprose S
(SAP) had shown Seaprose S to be better than Serratiopeptidase.
There were 3 studies in dental patients to see the postoperative
anti-inﬂammatory effects of Serratiopeptidase (Table 1).
In one study by Khateeb et al.,24 Serratiopeptidaseþ Paracetamol
combination was compared to Placeboþ Paracetamol in patients
after surgical removal of impacted third molars. It was concluded
that Serratiopeptidaseþ paracetamol group showed signiﬁcant
reduction in extent of cheek swelling and pain, but there was no
difference in mean maximal interincisal distance between the two
groups. Similar study by Chopra et al.25 comparing Serratiopeptidase
with ibuprofen/betamethasone/paracetamol/placebo showed ser-
ratiopeptidase group to have less mean pain scores and swelling as
compared to placebo but the difference was not statistically signiﬁ-
cant. Moreover, serratiopeptidase was not superior when compared
to ibuprofen and betamethasone. The third study by Surachai et al.26
in patients with postoperative swelling after removal of impacted
molars did not show any signiﬁcant difference in degree of facial
swelling in the Serratiopeptidase and no medication groups. It was
a trial with small sample size and study design not mentioned.
Further 5 studies in different otorhinolaryngology pathol-
ogies1,16e20 have tried to explore the mucolytic properties of ser-
ratiopeptidase. Two were placebo-controlled trials, among which
one study1 showed Serratiopeptidase reduced the symptoms of
severity of pain, amount and purulence of secretions but in the
second study16 outcomes were unclear. Another prospective, open
label study19 showed Serratiopeptidase to reduce the viscosity but
not the elasticity of secretions in patients of chronic sinusitis.
Similarly, one study20 in chronic airway disease patients compared
Serratiopeptidase with non-treatment group and concluded it to
reduce sputum viscosity, elasticity and neutrophil count. There was
only one study17 in chronic respiratory disease patients with dif-
ﬁculty in expectoration, where Serratiopeptidase was compared
with an active comparator Seaprose S and this study showed
Seaprose S to be better than Serratiopeptidase in relieving difﬁculty
in expectoration and speciﬁc symptoms.
In some studies21e23 the role of Serratiopeptidase in increasing
the effective concentration of antimicrobials in different tissues
was studied. These showed that Serratiopeptidase increased the
concentration of antimicrobials in tissues. But among these studies,
one was prospective open label trial.21 One of the studies22 did not
mention the duration of therapy and other was a randomised, open
label trial in which Serratiopeptidaseþ cefotiam was administeredfor prophylaxis before surgery, but again duration of treatment was
not given.
Bandolier27 online edition (retrieved on 1/5/2011) showed a re-
view “Serratiopeptidase-ﬁnding the evidence”. This review con-
cluded that therewere no trials of Serratiopeptidase for treatment of
back pain, neither therewere any trials for its use in heart attack and
stroke. Among the 9 RCTs included in this review which were gen-
erally said to be of poor methodological quality, ﬁve studies were
described as double-blind: one was completely un-interpretable,
three methodologically weak studies were positive and one trial of
apparent high quality was negative.
3.1. Evidence from clinical and preclinical studies
A total of 24 studies on efﬁcacy of Serratiopeptidase were
included which met the inclusion criteria. Among these 18 were
clinical and 6 were preclinical studies (Tables 1 and 2).
3.2. Clinical evidence
Serratiopeptidase has been used in Surgery (Traumatic and
postoperative inﬂammation,4,14 venous inﬂammatory disease,15
cystitis, epididymitis34), Orthopaedics (Traumatic swelling after
sports injury,4 carpal tunnel syndrome,7 osteoarticular infection to
increase antibiotic concentration at infection site21), Otolaryngology
(Sinusitis, rhinitis, laryngitis, bronchitis, inadequate expectoration of
sputum in bronchial asthma1,19,20), Gynaecology (Engorgement of
breasts5,35), Dentistry (Anti-inﬂammatory and to increase antibiotic
concentration at site of infection in periodontitis,36 pericoronitis of
wisdom tooth25).
The evidence from clinical studies has been graded according to
the checklist given by the Scottish Intercollegiate Guidelines Net-
work (SIGN).12 The grading showed that the studies supporting the
anti-inﬂammatory and analgesic role of Serratiopeptidase are
generally of poor methodology. Firstly the number of studies are
only few. Secondly, the studies which are there, either have a small
sample size (not more than 150 patients per group in any of the
studies) or are of short duration. Moreover, the studies are mostly
placebo-controlled trials and lack an active comparator. Also the
eligibility criteria and outcome variables are not well deﬁned and
ﬁnally the statistical methods used for analysing the signiﬁcance
level have not been explained (Table 1).
3.3. Studies in animals
The studies in animals are very few. These have only demon-
strated the anti-inﬂammatory effects of Serratiopeptidase. No
speciﬁc model has been used in any of these studies to screen for
the analgesic and anti-atherosclerotic effects of this enzyme in
particular (Table 2). In 3 animal studies28e30 Serratiopeptidase was
shown to increase the antimicrobial concentration at the site of
infection. While in 2 studies32,33 using anti-inﬂammatory animal
models it was shown that Serratiopeptidase demonstrated signiﬁ-
cant anti-inﬂammatory activity when compared to chymotrypsin,
trypsin, aspirin and diclofenac. In another study,31 where Serra-
tiopeptidase was compared to active comparator seaprose. Both
enzymes showed reduction in viscosity of sputum, but the duration
of therapy was not mentioned.
4. Source
Serratiopeptidase is derived from non-pathogenic enter-
obacteria belonging to genus Serratia species E-15. This micro-
organism was originally isolated during late 1960s from the
intestines of silkworm Bombyxmori which is its natural habitat.
Table 1
Evidence from clinical and preclinical studies (clinical studies).
Clinical
trial
Condition No. of patients Study design Treatment Control Duration Outcome Sign for
grading
evidence
Grading of evidence suggesting serratiopeptidase as anti-inﬂammatory agent
Esch et al.
19894
Postoperative and
traumatic swelling
(repair of lateral
collateral ligament
of knee)
66 Randomised Serratiopeptidase:
dose not speciﬁed
Application of
ice, leg elevation
and bed rest
Unclear Reduction in swelling by 50% on
third postoperative day and pain
disappeared by 10th day in TSP
group
1
Tsuyama
et al.13
Postoperative and
traumatic swelling
98/group in two
drug groups and 99
in
placebo group
Randomised and
double blind
Serratiopeptidase:
dose not speciﬁed
A-4700 tablet
and Placebo
Not stated A-4700 shown to be equally
effective to Serratiopeptidase
in improving symptoms and
reducing swelling
1
Tachibana
et al. 198414
Postoperative buccal
swelling
(Caldwell-luc
antrotomy)
174 (88 in TSP and
86 in placebo group)
Multicentre,
randomised,
double blind,
placebo-controlled
Serratiopeptidase
10 mg thrice daily
(30mg/day)
Placebo 7 days Buccal swelling reduced
signiﬁcantly in serratiopeptidase
group
1þ
Bracale
et al. 199615
Superﬁcial
thrombophlebitis
40 (20 per group) Randomised Serratiopeptidase
10 mg thrice daily
(30mg/day)
Seaprose S (SAP)
30 mg thrice
daily (90mg/day)
14 days 65% of TSP while 85% cases of
SAP showed improvement in
speciﬁc symptoms like pain,
erythema
1þ
Kee
et al. 19895
Breast engorgement 70 (35 per group) Randomised,
double blind
Serratiopeptidase:
10mg thrice daily
(30 mg/day)
Placebo 3 days Moderate to marked
improvement in breast pain,
swelling and induration seen in
TSP group
1þ
Panagariya
et al. 19997
Carpel tunnel syndrome 20 patient Prospective trial Serratiopeptidase:
10 mg twice daily
with initial short
course of nimesulide
e 6 weeks Clinical improvement seen in
65% patients
2
e Back pain, migraine No randomised
controlled trials
e e e e e e
Grading of evidence for its use in otorhinolaryngology pathologies
Mazzone
et al. 19901
Acute or chronic ear,
nose or throat disorder
193 (about 96 per
group)
Multicentre,
randomised,
double blind,
placebo-controlled
Serratiopeptidase
(2 tablets of 5 mg)
thrice daily, i.e.,
30 mg/day
Placebo (2 tablets
thrice daily)
7e8 days TSP showed good efﬁcacy in
reducing symptoms like severity
of pain, amount and purulence
of secretions, difﬁculty in
swallowing, nasal dysphonia
and obstruction and anosmia
1þ
Bellussi
et al. 1984 16
Secretory otitis media 75 Randomised and
double blind (for
50 patients)
Serratiopeptidase
(0.5 mg/kg/day)
Placebo 10 days Undeﬁned global judgement
Numerous tests but outcomes
unclear
1
Nagaoka
et al. 197917
Chronic respiratory
disease with difﬁcult
in expectoration
376 patients (125 in
Seaprose S, 128 in
TSP and 123 in
placebo group)
Multicentre,
randomised,
double-blind,
double dummy
Serratiopeptidase
(10 mg thrice daily)
Seaprose S (15 mg
thrice daily) and placebo
14 days No signiﬁcant difference
between two groups in showing
improvement in expectoration
and speciﬁc symptoms
1þ
Shimura
et al. 198318
Chronic respiratory
disease (not bronchial
asthma)
40 (<10/group) Randomised Serratiopeptidase
30 mg/day
Various mucolytic
agents as
comparator
7 days Relaxation of sputum
viscoelasticity
1
Majima
et al. 198819
Chronic sinusitis e Prospective, open label Serratiopeptidase
30 mg/day
e 4weeks TSP reduced the viscosity of
mucus but not its elasticity
2
S.Bhagat
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Nakamura
et al. 2003 20
Chronic airway disease 29 patient (15 in
treatment and 14 in
non-treatment
group)
Randomized,
open label trial
with non-treatment
control group
Serratiopeptidase
30 mg/day
No treatment 4 weeks TSP treatment decreased
sputum weight, % solid
component, viscosity and
elasticity, sputum neutrophil
count, and other symptoms
1
Grading of evidence for its role in increasing antimicrobial efﬁcacy
Okumura
et al. 1977 21
Osteoarticular
infection
8 patient Prospective, open
label
Serratiopeptidase
30 mg/dayþ
sulbenicillin
Sulbenicillin
alone
6 days TSP increased transfer of
sulbenicilin into exudates
2
Brewer science
library 199922
Perennial rhinitis,
chronic rhinitis
with sinusitis, chronic
bronchitis
93 patient Randomized, double
blind
Serratiopeptidaseþ
Cephalexin
Placeboþ
Cephalexin
e TSP group showed improvement
in rhinorrhoea, nasal stufﬁness,
coryza and paranasal sinus
shadow
1
Koyama
et al. 198623
Lung cancer patients
undergoing
thoracotomy
35 patient (18 in
serratioþ cefotiam
and 17 in cefotiam
alone group)
Randomized, open
label
Serratiopeptidase
(20 mg three times
per day)þ
Cefotiam 2 g
Cefotiam 2 g
single dose
Prophylaxis
before surgery
(days not
mentioned)
TSP group had signiﬁcant higher
level of antibiotic in tissues
1
Grading of evidence for use of serratiopeptidase in dentistry
Khateeb
et al. 2008 24
Surgical removal of
symmetrically
impacted mandibular
third molars
24 Prospective, intra-
individual,
randomized, double-
blind,
Cross-over study
Serratiopeptidase
5 mgþ Paracetamol
1000 mg
Placeboþ
paracetamol
1000 mg
7 days TSP group showed signiﬁcant
reduction in extent of cheek
swelling and pain intensity but
no difference in mean maximal
interincisal distance between 2 groups.
1þ
Chopra D
et al. 200925
Postoperative sequel
following removal of
impacted 3rd molar
150 patient divided
randomly into
5 groups
Randomized, double-
blind,
placebo-controlled
trial
Serratiopeptidase
(20 mg thrice daily)
Ibuprofen 600 mg
or betamethasone
0.5 mg or
paracetamol 1 g
or placebo each
given thrice daily
7 days TSP group showed less mean
pain scores and swelling as
compared to placebo but
difference not statistically
signiﬁcant. Also TSP not superior
when compared to ibuprofen
and betamethasone
1þ
Surachai
et al. 26
Postoperative swelling
after removal of
impacted molars
40 (20 per group) Not stated Serratiopeptidase
(5 mg thrice daily)
No medication 5 days No signiﬁcant difference in
degree of facial swelling and
maximum mouth opening seen
in two groups
2
TSP: serratiopeptidase, and SAP: seaprose.
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Table 2
Evidence from clinical and preclinical studies (preclinical studies).
Pre-clinical study Condition Animals Treatment Control Duration Outcome Conclusion
Mecikoglu
et al. 2006 28
Peri-prosthetic
infection
Rats, number
not speciﬁed
Serratiopeptidase
(TSP)þAntibiotic
(TSPþA)
Non-treatment (NT)
and antibiotic (A)
alone groups
2 weeks Infection persisted in 63.2%
in NT, 37.5% in A alone and
5.6% in TSPþA group
TSP effectively eradicated infection
and enhanced antibiotic efﬁcacy
Ishihara et al.
198329
Pleuritis and
pneumonitis
Rabbits Serratiopeptidase
(TSP)þ Cefotiam (C)
Cefotiam alone 30 minutes after
injection in jugular
vein
TSP increased plasma
concentration of cefotiam
in both conditions but
tissue concentration
increased only in pneumonitis
group a no change in pleuritis
group
TSP [ cefotiam efﬁcacy
Aratani et al.
198030
Gingival infection
by staphylococci
Rat Serratiopeptidase
(20 mg/kg)þ four
different antimicro-bials
(100 mg/kg per orally)
Antimicrobials alone
(Ciclacillin or
ampicillin or
cephalexin or
minocycline)
Not mentioned TSP [ gingival concentration
of all four antimicrobial
TSP enhanced the efﬁcacy of
antimicrobials
Kase et al.
198231
Subacute
bronchitis
Rabbit Serratiopeptidase
(20 mg/kg)
Seaprose (SAP)
30 mg/kg
After intra-duodenal
administration
TSP and SAP signiﬁcantly
reduced viscosity of sputum
(p< 0.05) at 1e3 h and 4e6 h,
respectively
Both enzymes have mucolytic
activity
Jadav et al.
201032
Paw edema
model
Albino rats Serratiopeptidase
(TSP) 10 and 20 mg/kg
Diclofenac
0.5 mg/kg
1, 2, 4 and 8 h after
intraplantar formalin
injection
TSP at both doses signiﬁcantly
inhibited acute inﬂammation
of paw (p< 0.0001) and result
comparable with diclofenac
TSP signiﬁcantly showed
anti-inﬂammatory activity.
Viswanatha
Swamy 200833
Hind paw edema
model and cotton
pellet induced
granuloma
Albino rats Serratiopeptidase (TSP) Chymotrypsi (Ch),
Trypsin (T) and
2Aspirin (As)
3 h TSP showed better
anti-inﬂammatory activity as
compared to Ch, T, and As
Serratiopeptidase showed
signiﬁcant anti-inﬂammatory
activity
TSP: serratiopeptidase, A: antibiotic, and SAP: seaprose.
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REVIEWThe enzyme helps the emerging moth to dissolve its cocoon. Ser-
ratiopeptidase is produced by puriﬁcation from culture of Serratia
E-15 bacteria.37
5. Chemistry
Several strains of bacteria have been isolated from the intestinal
canal of silk worms,38 of which ﬁve species of Serratia have been
identiﬁed which are all gelatinoytic and produce extracellular
protease. These include S. indica, S. marcescens, S. plymuthica, S.
piscatorum, S. species E-15.37 Out of these Serratia species strain E-
15 produces proteases over three times as much as that produced
by Serratia marcescens, which is a known protease-producing or-
ganism. The Serratia protease enzyme has a molecular weight of
45,000e60,000 and is a metalloprotease containing a zinc atom
which is important for its proteolytic activity. The amino acid
sequence deduced from the nucleotide sequence of the gene
encoding for the enzyme reveals that the mature protein of the
Serratia protease consists of 470 amino acids.39 The enzyme was
characterized to be free of any sulphur-containing aminoacids like
cysteine and methionine. It has been shown that such a type of
enzyme protein was found as a protease in Pseudomonas aerugi-
nosa40 and Aspergillus oryzae.41 The enzyme showed maximal
activity at pH 9.0 and at a temperature of 40 C. The enzyme is
completely inactivated by heating at 55 C for 15 min.37
6. Pharmacokinetics
After oral administration, Serratiopeptidase is absorbed through
the intestines and transporteddirectly into thebloodstream.42,43 But
being a peptide there would be a high propensity of this enzyme to
undergoenzymatic degradation in the gastrointestinal tract and low
membrane permeability due to the hydrophilic nature of peptides
and proteins in general.44,45 So these factors could lead to low bio-
availability of this enzyme when used therapeutically.
The intestinal absorption of Serratiopeptidase was assessed by
measuring its concentration in plasma, lymph and extract of in-
ﬂammatory tissue of rats by sandwich enzyme immunoassay (EIA)
technique.42,43 Serratiopeptidase was administered orally to rats
and was detected from plasma at 30 mg/kg dose and in lymph at
1 mg/kg. Its concentrations in plasma and lymph were dose
dependent. It was seen that the peak concentration in plasma and
lymph at a dose of 100 mg/kg were 0.87 0.41 and 43 42 ng/ml,
respectively, and this peak plasma concentration was achieved
0.25e0.5 h after the dose and disappeared by 6 h. Serratiopeptidase
was also detected in carrageenan-induced inﬂammatory tissue in
animals at concentrations higher than that in plasma. It was con-
cluded in the study that Serratiopeptidase is absorbed from the
intestine, distributed to the inﬂammatory site via blood or lymph.
Thus, indicating that orally administered Serratiopeptidase is
absorbed from intestinal tract and reaches circulation in an enzy-
matically active form.42,43 In rat blood it exists as a complex with
plasma protease inhibitor alpha-1 macroglobulin (a1M) with
amolar binding ratio of 1:1 which helps to mask its antigenicity but
still retains 20% of its original caseinolytic activity.3 However,
pharmacokinetic data including its oral bioavailability in humans is
not mentioned anywhere nor is the speciﬁc concentration required
for its therapeutic action.
7. Pharmacodynamics
Serratiopeptidase is thought to work in three ways.
1. Anti-inﬂammatory: serratiopeptidase reduces swelling by the
process of decreasing the amount of ﬂuid in the tissues,thinning the ﬂuid, and by facilitating the drainage of ﬂuid. In
addition, its enzyme activity dissolves dead tissue surrounding
the injured area so that healing is accelerated.5,6 It may also act
by modifying cell-surface adhesion molecules that guide in-
ﬂammatory cells to their target site of inﬂammation. These
adhesion molecules play an important role in the development
of arthritis and other autoimmune diseases.6
2. Analgesic: it may help alleviate pain by inhibiting the release of
pain-inducing amines like bradykinin from inﬂamed tissues.1
3. Fibrinolytic/caseinolytic: it may be beneﬁcial in atherosclerotic
disease as it acts by breaking down ﬁbrin and other dead or
damaged tissue without harming living tissue. This could
enable the dissolution of blood clots, and atherosclerotic
plaques.22
8. Formulation
Being a protein the major challenge in developing a for-
mulation for this enzyme has been to retain the backbone and
folding structure of this enzyme protein during manufacturing,
storage and also during digestion and absorption in the stomach
and intestines.46 To overcome degradation by enzymes in the
gastrointestinal tract, Serratiopeptidase is available as an enteric
coated tablet. This enteric coating consists of pH sensitive poly-
mers which remains intact in the gastric acidic pH (1.5e3.5) and
solubilises in the more favourable alkaline pH (6.5e7.6) of the
small intestines.47
9. Safety
There are not many published reports of Adverse Drug Reactions
(ADRs) to Serratiopeptidase. The only information available is drug
companies monographs. The ADRs include allergic skin reactions
which could range from dermatitis to extreme cases of Stevense
Johnson syndrome or erythema multiforme, muscle aches and
joint pains, gastric disturbances like anorexia, nausea and
abdominal upset, cough rarely pneumonitis48 and coagulation
abnormalities.
10. Dosage
The dose which has been used in clinical studies and mentioned
in drug monographs ranges from 10 mg to 60 mg per day. It has to
be taken on an empty stomach or at least two hours after eating,
and no food should be consumed for about half an hour after taking
Serratiopeptidase. The recommended dose of Serratiopeptidase for
speciﬁc indications, in particular is not mentioned anywhere.
The enzyme activity is measured in units. Serratiopeptidase
10 mg is equal to 20,000 units of enzyme activity.
11. Drug interactions
There are no clinical studies reporting any drug interactions. The
only available information is by drug company monographs.
If administered along with Warfarin, Clopidogrel or Aspirin as
well as with other natural remedies such as garlic, ﬁsh oil and
turmeric, there may be increased risk of bleeding or bruising.
12. Discussion
Serratiopeptidase, a proteolytic enzyme, has been used for
almost 40 years in Japan and Europe for pain and inﬂammation.
It is usually available as a ﬁxed dose combination with various
Non Steroidal Anti-inﬂammatory Drugs (NSAIDs) like diclofenac,
aceclofenac, paracetamol. It is also given along with various
S. Bhagat et al. / International Journal of Surgery 11 (2013) 209e217216
REVIEWantimicrobials to increase their tissue penetration, e.g. cephalexin,
cefotiam, sulbenicillin, etc., by its proteolytic effects.
When combined with NSAIDs it acts as an anti-inﬂammatory
agent. But the efﬁcacy of Serratiopeptidase alone as an anti-
inﬂammatory agent needs to be evaluated in a more elaborate
way. In particular the analgesic activity of Serratiopeptidase, which
is said to be due to its ability to block the release of biogenic amines,
needs to be evaluated in a more comprehensible way by using
appropriate analgesic animal screening models. The evidence
showing its anti-atherosclerotic effects is only anecdotal. Thus,
further extensive clinical studies are needed to prove its worth to
be used as a health supplement. There are 2 animal and 8 clinical
studies (including 2 studies in dental patients) supporting its use as
anti-inﬂammatory agent but larger, well-designed, controlled trials
are warranted to clearly prove its efﬁcacy. Also data on tolerability
and long-term safety of this enzyme is lacking. This may be of
particular relevance when it is prescribed to patients for anti-
atherosclerotic effects.
During the preparation of this review we have done a thorough
search of the literature to include all the relevant studies dealing
with the efﬁcacy of Serratiopeptidase, but it is possible that some
studies may have been missed which have not been published or
registered with any of these search engines. Further retrieving all
the information from the past is not always possible. Moreover,
during grading using SIGN checklist, separate reviewers did the
grading and then coordinated together to validate the ﬁnal grading.
Any disagreement between the two reviewers was resolved by
discussion with the third reviewer. This was done to minimise bias
but still the risk of bias cannot be ruled out completely.
Until there is clear scientiﬁc evidence supporting the efﬁcacy
of Serratiopeptidase as anti-inﬂammatory, analgesic and anti-
atherosclerotic agent, it is not rationale to prescribe this
enzyme on the basis of few studies whose scientiﬁc credibility is
still not very clear. Thus in future, more well-designed, active
comparator controlled trials are needed to clearly deﬁne the
beneﬁcial effects of this natural enzyme claiming to possess
miraculous properties.
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